PCI Pharma, a Philadelphia-based CDMO, unveiled plans to expand operations at its Tredegar, Wales, manufacturing operations as part of the company’s push into targeted oncology therapies.

The project amount wasn’t disclosed, but the company said that it will add two new facilities focussed on manufacturing and packaging solid oral dose tablets and capsules.

A second contained manufacturing building—the first was opened in 2013—will allow PCI to double its large-scale processing capacity at the site. The new packaging facility will feature primary and secondary blistering and bottling suites.

The project is expected to create about 40 new jobs in the first year, the company said. PCI, which employs about 500 at the site, has operated the plant for more than four decades.